| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
100,490,000 |
| Market
Cap: |
7.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.24 - $94.5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. Co.'s primary clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRss). Co. is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRss for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
348,181 |
852,260 |
908,260 |
1,615,026 |
| Total Sell Value |
$27,122,482 |
$40,299,016 |
$41,683,016 |
$54,614,939 |
| Total People Sold |
2 |
4 |
6 |
6 |
| Total Sell Transactions |
2 |
9 |
11 |
23 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mancini Marianna |
Chief Operating OfficerOfficer |
• – – |
2021-01-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
94,655 |
|
2% |
|
| Lian Brian |
President & CEO |
• • – |
2021-01-04 |
4 |
D |
$5.80 |
$98,443 |
D/D |
(16,973) |
1,899,792 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
204,333 |
1,916,765 |
|
- |
|
| Mancini Marianna |
Chief Operating Officer |
• – – |
2021-01-04 |
4 |
D |
$5.80 |
$16,083 |
D/D |
(2,773) |
171,632 |
|
- |
|
| Mancini Marianna |
Chief Operating Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
79,750 |
174,405 |
|
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2021-01-04 |
4 |
D |
$5.80 |
$15,886 |
D/D |
(2,739) |
117,747 |
|
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
21,334 |
120,486 |
|
- |
|
| Zante Greg |
Chief Financial Officer |
• – – |
2021-01-04 |
4 |
D |
$5.80 |
$16,165 |
D/D |
(2,787) |
90,559 |
|
- |
|
| Zante Greg |
Chief Financial Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
71,450 |
93,346 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2021-01-03 |
4 |
D |
$5.63 |
$177,598 |
D/D |
(31,545) |
1,712,432 |
|
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2020-09-15 |
4 |
D |
$6.25 |
$9,731 |
D/D |
(1,557) |
97,873 |
|
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2020-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
99,430 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2020-09-15 |
4 |
D |
$6.25 |
$119,950 |
D/D |
(19,192) |
1,742,363 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2020-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
55,500 |
1,761,555 |
|
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2020-08-26 |
4/A |
S |
$8.11 |
$1,205,660 |
D/D |
(148,700) |
5,819,383 |
|
- |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2020-08-26 |
4 |
S |
$8.11 |
$766,109 |
D/D |
(94,488) |
5,819,383 |
|
11% |
|
| Ligand Pharmaceuticals Inc |
10% Owner |
– – • |
2020-08-25 |
4 |
S |
$8.02 |
$561,575 |
D/D |
(70,000) |
5,968,083 |
|
21% |
|
| Foehr Matthew W |
Director |
– • – |
2020-06-30 |
4 |
S |
$7.35 |
$95,550 |
D/D |
(13,000) |
26,250 |
|
14% |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2020-01-19 |
4 |
D |
$7.18 |
$14,676 |
D/D |
(2,044) |
92,840 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2020-01-19 |
4 |
D |
$7.18 |
$22,940 |
D/D |
(3,195) |
1,704,312 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2020-01-03 |
4 |
D |
$7.77 |
$52,696 |
D/D |
(6,782) |
1,707,507 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2020-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
153,333 |
1,714,289 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2019-01-19 |
4 |
D |
$8.78 |
$38,044 |
D/D |
(4,333) |
1,560,152 |
|
- |
|
| Morneau Michael |
VP, Finance and Administration |
• – – |
2019-01-19 |
4 |
D |
$8.78 |
$17,946 |
D/D |
(2,044) |
91,991 |
|
- |
|
| Lian Brian |
President & CEO |
• • – |
2019-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
80,897 |
1,564,485 |
|
- |
|
162 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
6.56 (8.18%) 
